Research article

Cyclooxygenases and prostaglandin E₂ receptors in growth plate chondrocytes in vitro and in situ – prostaglandin E₂ dependent proliferation of growth plate chondrocytes

Christoph Brochhausen¹, Pia Neuland², C James Kirkpatrick¹, Rolf M Nüsing³ and Günter Klaus²

¹Institute of Pathology, Johannes Gutenberg-University, Mainz, Germany
²Department of Pediatrics, Philipps-University, Marburg, Germany
³Institute of Clinical Pharmacology, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany

Corresponding author: Günter Klaus, klaus@med.uni-marburg.de

Received: 26 Aug 2005 Revisions requested: 28 Sep 2005 Revisions received: 16 Mar 2006 Accepted: 28 Mar 2006 Published: 28 Apr 2006

Arthritis Research & Therapy 2006, 8:R78 (doi:10.1186/ar1948)

© 2006 Brochhausen et al.; licensee BioMed Central Ltd.

Abstract

Prostaglandin E₂ (PGE₂) plays an important role in bone development and metabolism. To interfere therapeutically in the PGE₂ pathway, however, knowledge about the involved enzymes (cyclooxygenases) and receptors (PGE₂ receptors) is essential. We therefore examined the production of PGE₂ in cultured growth plate chondrocytes in vitro and the effects of exogenously added PGE₂ on cell proliferation. Furthermore, we analysed the expression and spatial distribution of cyclooxygenase (COX)-1 and COX-2 and PGE₂ receptor types EP1, EP2, EP3 and EP4 in the growth plate in situ and in vitro.

PGE₂ synthesis was determined by mass spectrometry, cell proliferation by DNA [³H]-thymidine incorporation, mRNA expression of cyclooxygenases and EP receptors by RT-PCR on cultured cells and in homogenized growth plates. To determine cellular expression, frozen sections of rat tibial growth plate and primary chondrocyte cultures were stained using immunohistochemistry with polyclonal antibodies directed towards COX-1, COX-2 and PGE₂ receptor types EP1, EP2, EP3 and EP4. Cultured growth plate chondrocytes transiently secreted PGE₂ into the culture medium. Although both enzymes were expressed in chondrocytes in vitro and in vivo, it appears that mainly COX-2 contributed to PGE₂-dependent proliferation. Exogenously added PGE₂ stimulated DNA synthesis in a dose-dependent fashion and gave a bell-shaped curve with a maximum at 10⁻⁸ M. The EP1/EP3 specific agonist sulprostone and the EP1-selective agonist ONO-D1-004 increased DNA synthesis. The effect of PGE₂ was suppressed by ONO-8711. The expression of EP1, EP2, EP3, and EP4 receptors in situ and in vitro was observed; EP2 was homogenously expressed in all zones of the growth plate in situ, whereas EP1 expression was inhomogenous, with spared cells in the reserve zone. In cultured cells these four receptors were expressed in a subset of cells only. The most intense staining for the EP1 receptor was found in polygonal cells surrounded by matrix. Expression of receptor protein for EP3 and EP4 was observed also in rat growth plates. In cultured chondrocytes, however, only weak expression of EP3 and EP4 receptor was detected. We suggest that in growth plate chondrocytes, COX-2 is responsible for PGE₂ release, which stimulates cell proliferation via the EP1 receptor.

Introduction

Prostaglandins, especially prostaglandin E₂ (PGE₂), play an important role in bone and cartilage metabolism. Although PGE₂ was initially described as a potent bone-resorbing substance [1], several studies have demonstrated its activity in bone-forming processes [2,3]. In osteoblast-like cells, endogenous PGE₂ was shown to affect proliferation and differentiation by stimulation of DNA synthesis and alkaline phosphatase activity [4]. An interesting aspect in the investigation of the function of prostaglandins in cartilage or bone tissue is their possible role in the growth plate. This special cartilage tissue is responsible for the endochondral ossification of long bones and represents all differentiation steps in distinguishable layers, from undifferentiated reserve zone cells to proliferative and hypertrophic chondrocytes, which initiate cartilage mineralisation. Due to this complex structure of the growth plate, cellular effects of prostaglandins on growth plate chondrocytes have been examined using various in vitro systems.
PGE₂ elicits differentiation of chondrocytes, as previously shown for the chondrocyte cell line RCJ3.1C5.18 [5] and rat growth plate chondrocytes [6]. In the latter, the effect of PGE₂ was mediated by cAMP and protein kinase C. Furthermore, PGE₂ also makes an important contribution to cartilage formation and promotes DNA and matrix synthesis in growth plate chondrocytes [7]. In addition to various findings in vitro, the physiological role of prostaglandins was clarified by its stimulating effect on bone formation and by the increase in bone mass after systemic administration of PGE₂ to infants [8] and animals [9]. Furthermore, local administration of PGE₂ resulted in osteogenesis in situ [10,11].

The rate-limiting step for the synthesis of PGE₂ and other prostaglandins is the conversion of arachidonic acid to prostaglandin endoperoxide by cyclooxygenase (COX), which exists in two isoforms, COX-1 and COX-2 [12]. These enzymes are differentially regulated. Previous in vitro analysis demonstrated the functional importance of COX-1 for proliferation, differentiation and matrix production in cultured growth zone chondrocytes [13]. In various chondrocyte cell models, as well as in fracture callus formation, COX-2 may also be important for prostaglandin synthesis [14]. Moreover, the expression of COX-2 is regulated by different stimuli, such as tumour necrosis factor-α [15] or shear stress [16]. The induction of COX-2 is regarded as an important step in inflammatory situations. COX-1 and COX-2 are expressed in inflamed bone tissue [17] and COX inhibitors are extensively used in the treatment of rheumatoid arthritis. However, inadequate information is available on in situ expression of both COX-1 and COX-2 within the growth plate to correlate in vitro findings with the in situ situation.

PGE₂, the principal product of bone prostaglandin synthesis, acts locally on target cells by binding to prostaglandin E (EP)-type G protein-coupled receptors. Four different EP receptors are known, which are linked to different intracellular signal transduction pathways [18]. The EP1 receptor is coupled to intracellular Ca²⁺ mobilization, while the EP2 and EP4 receptors increase intracellular cAMP accumulation. By contrast, EP3 inhibits intracellular cAMP accumulation. Regarding bone formation and bone resorption, the EP4 receptor has been shown to be essential in terms of PGE₂ action in bone [19]. Recently, the EP2 and EP4 receptors were shown to be required for PGE₂-dependent chondrocyte differentiation [20]. In previous studies, we demonstrated that stimulation of growth plate chondrocyte proliferation by both calcitropic hormones, 1,25(OH)₂D₃ and parathyroid hormone, is dependent on an increase in intracellular calcium and activation of protein kinase C [21]. On the other hand, an increase in intracellular cAMP concentration was without any effect on proliferation [21], but was able to stimulate matrix synthesis [22]. In the present study, we were interested in whether PGE₂ acts in a proliferative and stimulatory fashion on growth plate chondrocyte function. We therefore investigated the effects of PGE₂ and prostaglandin receptor agonists and antagonists on cultured growth plate chondrocytes. Furthermore, we analysed the expression and spatial distribution of COX-1 and COX-2 and the PGE₂ receptors EP1, EP2, EP3, and EP4 in the growth plate and compared this profile with their expression in cultured growth plate chondrocytes in order to give innovative insights into in situ -in vitro correlations.

**Materials and methods**

**Materials**

Polyclonal rabbit antibodies against the EP1, EP2, EP3 and EP4 receptors and COX-1 and COX-2 were described previously [23,24]. Polyclonal rabbit antibodies against collagen (Col) type I and type II were purchased from Biotrend Chemicals GmbH (Cologne, Germany). Monoclonal anti-collagen type X antibody (mouse) was from Quartett (Berlin, Germany). All other antibodies used were obtained from DAKO (Glostrup, Denmark). DNase (10 U/µl) for cartilage digestion was from Amersham Pharmacia Biotech (Piscataway, NY, USA) and CaCl₂ was from Serva (Heidelberg, Germany). FCS and culture dishes were from Greiner (Frickenhausen, Germany), and culture media were obtained from PAA GmbH (Linz, Austria). Butaprost, misoprostol, sulprostone and PGE₂ were purchased from Cayman Chemical Company (Ann Arbor, Michigan, USA). Ligands for the PGE₂ receptors (ONO D1-004, ONO AE1-259-001, ONO AE-248, ONO AE1-329, and ONO-8711) have been described previously [25-27] and were kindly provided by Dr Maruyama (ONO Pharmaceuticals, Osaka, Japan). PicoGreen for double-stranded (ds)DNA quantification was obtained from Mobitec (Göttingen, Germany). Gene Amp RNA-PCR kit, DNA Polymerase Amplify (AmpliTaq Gold), reverse transcriptase (MuLV RT) and oligo (dT)₁₆ were purchased from Perkin Elmer, Roche Molecular Systems Inc. (Branchburg, NJ, USA). Other chemicals were of p.a. grade and purchased from Merck (Darmstadt, Germany), Gibco BRL Life Technologies (Karlruhe, Germany) or Sigma Aldrich Chemistry (Steinheim, Germany).

**Cell culture**

**Isolation of chondrocytes**

Chondrocytes were isolated and cultured as described earlier by Benya and Shaffer [28] and modified according to Klaus and colleagues [21]. Briefly, femurs of up to four week old Sprague Dawley rats (60 to 80 g each) were dissected. The epiphyseal growth plate of the tibiae was separated by cleaning the cartilage plate of muscular tissue, periosteum and perichondrium. The proximal epiphysis was divided by a transverse cut with a sharp scalpel, and the cartilage plate was separated distally from the calcification zone of the tibial metaphysis. Isolated growth plates were digested for 3 hours at 37°C by collagenase (0.12% w/v) and DNase (0.02% w/v) in 5 ml of serum free F12/DMEM medium. After thorough washing, cells were counted using a Neubauer chamber. Viability, examined by trypan blue exclusion, was > 95%.


Monolayer cultures
Chondrocytes were cultured in flasks, 96-well-plates or 2-well cell-tissue-chambers containing F12/DMEM 1/1 medium supplemented with 10% FCS, 10 mM HEPES, 2 mM pyruvate, 2 mM L-glutamine, 0.7 µM CaCl₂, 10 mg/ml penicillin/streptomycin and L-cysteine. Ionized calcium measured by a calcium-sensitive electrode was 1.2 mmol/l. During the first four days of cell culturing the serum substitute Ultroser-G (1%) was added to the medium. From day 5 on, β-glycerophosphate (10 mM) and L-thyroxine (100 µg/ml), as well as ascorbic acid (5 to 60 µg/ml) from day 11 on, were added to the culture medium. Medium was changed every 48 hours and cells became confluent within 6 to 12 days.

Assay of cell proliferation: semiquantitative dsDNA determination
Primary cultures of chondrocytes were transferred to 96-well-plates in serum-free medium without L-thyroxine, which is reported to exert antiproliferative effects [29]. Cell cycles were synchronised for 24 hours as described earlier [21].

PGE₂, EP receptor agonists, or vehicle were added with fresh medium, supplemented with 10% FCS and cells were stimulated for 24 or 48 hours. Incubation was stopped by aspiration of the supernatants and the culture plates were frozen at -80°C for 1 hour. Thereafter, cells were thawed and incubated with 200 µl staining solution (containing 2.5 µl/ml PicoGreen) for 10 minutes under light protection. Optical density was determined using a plate reader (excitation/emission, 485 nm/530 nm). Experiments were run with four to six parallel aliquots.

Assay of cell proliferation: [3H]-thymidine incorporation
Incorporation of [3H]-thymidine was determined in serum-free cultures as described previously [21]. Cells were synchronised in serum-free medium for 24 hours. Thereafter, medium was changed to F-12/DMEM with 0.2% (w/v) bovine serum albumin and the substances or vehicles were added. Cells were incubated for 48 hours and 2 µCi [3H]-thymidine were added to each well 3 hours before stopping the incubation.

Reverse transcriptase-polymerase chain reaction
Total RNA was isolated from first passage monolayer cultures of chondrocytes and from two to eight freshly isolated epiphyseal growth plates that were pulverised in liquid nitrogen. After DNase digestion, 1.2 µg (from cells) or 0.5 µg (from tissue) RNA was transcribed into cDNA using oligo dT. RT-PCR was performed for EP1, EP2, EP3, EP4, COX-1, COX-2, Col I, Col II, β-actin, Col, collagen; COX, cyclooxygenase; EP, prostaglandin E receptor.

### Table 1

| mRNA | Sequence of primer | Product (bp) | Accession numbers |
|------|-------------------|--------------|------------------|
| EP-1 | 5' -GCT GTA CGC CTC GCA TCG TGG-3' | 404 | NCBI:D16338 |
| EP-2 | 5' -GAA CGC TAC CTG TCC ATC AGG-3' | 415 | NCBI:D50589 |
| COX-1EP-3 | 5' -TTTGGTCTG GCCTTCTAGA AC-3' | 399,359 | U03388 NCBI:D14869 |
| COX-2EP-4 | 5' -AAATGAGTACC GCAA-3' | 420,407 | NM011198NCBI:D28860 |
| Col ICOX-1 | 5' -TGGTGAAGA GGTAGACAG3- | 329,389 | Z78279NCBI:U03388 |
| Col ICOX-2 | 5' -TTTGACTG GTG CTG TCTAGAG-3' | 261,420 | NM012929NCBI:NM011198 |
| Col XI | 5' -TCCCTCCTG TGGGTTAAC C-3' | 248 | AJ131848NCBI:Z78279 |
| β-actinCol II | 5' -CATACACT GGCAATGAG G-3' | 403,261 | NM031144NCBI:NM012929 |
| Col X | 5' -TGCCCTCTG TGGGTTAAC C-3' | 248 | NCBI:AJ131848 |
| β-actin | 5' -CATACACT GGCAATGAG G-3' | 403 | NCBI:NM031144 |

Col, collagen; COX, cyclooxygenase; EP, prostaglandin E receptor.
Arthritis Research & Therapy  Vol 8 No 3  Brochhausen et al.

II, Col X and β-actin. Primers used in this study are listed in Table 1. The amplification profile consisted of denaturation at 95°C for 30 seconds, annealing at 54°C (EP receptors and COX) or at 57°C (collagens) for 45 seconds and extension of DNA at 72°C for 30 seconds after a 10 minute denaturation step at 95°C. When using RNA from bone tissue, the number of cycles were 40 for the EP receptors and 45 for the collagen types, and when using RNA from cultured chondrocytes, 35 cycles and 30 cycles, respectively, were performed. The amplification products of 10 µl of each PCR reaction were separated on a 1.8% agarose gel, stained with ethidium bromide, and visualised by ultraviolet irradiation. Identification of amplification products was determined by size and dideoxy sequencing.

Immunohistochemistry
For immunohistochemistry, the epiphyseal plate with neighbouring bony metaphysis and epiphysis including the knee joint were dissected. The isolated tissue was immediately frozen in isopentane at -80°C. For detection of EP1, EP2, EP3, EP4, COX-1, COX-2, Col II and Col X, the alkaline-phosphatase-anti-alkaline-phosphatase method was used according to Cordell and colleagues [30] as modified by Bittinger and colleagues [31]. Frozen sections (4 µm) were fixed in paraformaldehyde (4%). Polyclonal rabbit antibodies against EP1 (1:300), EP2 (1:200), EP3 (1:300), EP4 (1:300), COX-1 (1:100), COX-2 (1:100) and Col II (1:800) as well as a monoclonal mouse antibody against Col X (1:200) were incubated for 16 hours at 4°C. After staining, these sections were counter-stained with hemalaun. For the antibodies directed against the EP receptors, the following controls were performed. Firstly, the primary antibody was omitted; under this condition no staining was visible. Secondly, the antibodies were preabsorbed with the corresponding peptide against which they are directed as described previously [24]; under this condition staining was completely blocked.

Determination of PGE2
PGE2 was determined in cell supernatants as described previously [32].

Statistical analysis
Statistical analysis was carried out by t test or ANOVA as appropriate. P values are < 0.05 or < 0.001.

Results
Collagen expression in cultured chondrocytes
To define the differentiation stage of cultured chondrocytes we first studied the expression of various collagens. Col I is typically expressed towards the metaphyseal zone, whereas Col II is present in the proliferation zone and Col X in the hypertrophic zone. Proliferating cells express Col II and Col X is strongly expressed after the transition from pre-hypertrophic,
proliferating chondrocytes to hypertrophy. Accordingly, we observed staining for Col II mainly in the proliferative zone and Col X in the hypertrophic zone of the growth plate (data not shown). In cultured chondrocytes, we observed strong staining for Col II in more than 90% of the cells but no antigenicity towards the anti-Col X antibody (Figure 1a). In addition, Col I was expressed in cultured chondrocytes. In support of this observation, we obtained strong amplification with specific primers for Col I and Col II, but weak amplification with oligonucleotides specific for Col X in the cultured chondrocytes (marked by arrow) of a sub-population of the cultured cells only. r, reserve zone; p, proliferative zone; h, hypertrophic zone.

### Cyclooxygenase (COX) expression in rat growth plate chondrocytes in vitro and in situ

Protein expression of COX-1 and COX-2 was studied using isoform-specific antibodies. Both COX isoforms could be detected in all zones of the growth plate. In cultured growth plate chondrocytes, COX-1 was expressed in all cultured chondrocytes with high intensity in paranuclear areas (marked by arrow). COX-2 protein was detected in extranuclear regions as well as in cell processes (marked by arrow) of a sub-population of the cultured cells only. r, reserve zone; p, proliferative zone; h, hypertrophic zone.

### PGE2 production and COX-1 and COX-2 expression

Isolated rat growth plate chondrocytes released PGE2 transiently into the supernatants. Within the first 48 hours, a four-fold increase in PGE2 concentration was observed (Table 2). After six days of culture, however, PGE2 release by subconfluent, slowly proliferating cells was reduced almost to baseline levels.

To determine the COX isofrom involved in PGE2 synthesis, we analysed mRNA and protein expression of COX-1 and COX-2 in growth plates as well as in cultured chondrocytes. Regarding mRNA expression, both growth plates and cultured chondrocytes expressed COX-1 and COX-2 mRNA (Figure 2). Isoform-specific antibodies were used to determine COX distribution in rat growth plate tissue and in cultured rat chondrocytes. To ensure specificity, the following control experiments were performed: firstly, the primary antibody was omitted; and secondly, for COX-2, the antibodies were preabsorbed with the corresponding peptide against which they are directed, as described previously [24]. Under these conditions, no staining was visible (data not shown). On the protein level, growth plates as well as cultured chondrocytes expressed both COX isoforms (Figure 3). Growth plate chondrocytes in situ showed intracellular expression of both COX isoforms. Regarding the spatial distribution of COX expression in the different zones of the growth plate, a dispa-rate expression pattern of COX-1 and COX-2 was observed. COX-1 stained chondrocytes in all zones of the growth plate strongly and homogenously, whereas COX-2 appeared to be only moderately expressed in the reserve zone cells but strongly expressed in the other zones of the growth plate. In cultured chondrocytes, COX-1 expression appeared to be predominantly in the perinuclear region, whereas COX-2 expression dominated in the dendritic processes of all cells. To further investigate the role of the COX isoform in chondrocyte proliferation, we blocked both isofrom activities with the unspecific inhibitor indomethacin and each of the isoforms with the specific COX-1 inhibitor SC-560, or the COX-2 inhibitor SC-236. Indomethacin suppressed chondrocyte proliferation as assessed by thymidine incorporation (Figure 4). A similar extent of proliferation inhibition was achieved by the addition of the COX-2 inhibitor SC-236 but not SC-560. This indicates that COX-2 is primarily important for chondrocyte proliferation.
Effect of prostaglandin E₂ (PGE₂) on chondrocyte proliferation. (a) Proliferation of cultured chondrocytes was determined by [³H]-thymidine incorporation. Subconfluent chondrocytes were synchronized in serum-free medium for 24 hours. Medium was renewed and PGE₂ or solvent was added in the indicated concentrations for 24 hours. Data are presented as mean ± standard error of the mean, n = 5. (b) Relative quantification of DNA in cultured chondrocytes was used as a measure for proliferation. Chondrocytes were grown in 96-well-plates until subconfluency. After synchronization, PGE₂ or solvent was added for 24 hours. Thereafter, medium was aspirated, DNA was extracted by freeze-thawing and 200 µl of the staining solution (containing a fluorescent nucleic acid stain) were added and DNA-bound fluorophore was determined by fluorescence spectroscopy, expressed as OD at 530 nm. Data are presented as mean ± standard error of the mean of four parallel experiments, given as percent of the control. Excitation of the control was 14,705 ± 2,675 after 24 hours. *p value < 0.05.

Effect of PGE₂ and analogues on proliferation of growth plate chondrocytes

To analyse whether PGE₂ might stimulate cell proliferation in an autocrine or paracrine manner, we studied the effect of exogenously added PGE₂ in cultured rat chondrocytes. Cell cycles were synchronized by 24 hour starving. DNA synthesis was determined by [³H]-thymidine incorporation and DNA content by fluorescence spectroscopy. In a bell-shape manner, PGE₂ stimulated DNA synthesis with a maximum at 10 nM PGE₂ (Figure 5a). The proliferative effect of PGE₂ was also observed by semiquantitative determination of DNA content (Figure 5b).

Effect of prostaglandin E (EP) receptor ligands on proliferation of cultured chondrocytes. (a) Unselective and selective EP receptor agonists were administered to cultured chondrocytes. Subconfluent chondrocytes were synchronized in serum-free medium for 24 hours and EP receptor agonists were added for 24 hours. Proliferation was assessed by [³H]-thymidine incorporation. C, control; Sul, 1 µM sulprostone; Miso, 1 µM misoprostole; But, 1 µM butaprost; EP1A, 4 µM ONO-D1-004; EP2A, 0.1 µM ONO-AE1-259-01; EP3A, 0.1 µM ONO-AE-248; EP4A, 0.1 µM ONO-AE1-329. Data are given as mean ± standard error of the mean, n = 5. *p value < 0.05. (b) To study EP1 function for cell growth, a EP1 receptor selective agonist and antagonist were added to cultured chondrocytes. Subconfluent chondrocytes were synchronized in serum-free medium for 24 hours and EP1 receptor agonist (EP1A) or antagonist (EP1AN) combined with 10 nM prostaglandin E₂ were added for 24 hours in the presence of [³H]-thymidine. EP1A, 4 µM ONO-D1-004; EP1AN, 1 µM ONO-8711. Data are given as mean ± standard error of the mean, n = 5. *p value < 0.05.

To define the EP receptor(s) involved in PGE₂ signalling in this experimental setting, we used agonists for the various EP receptor types. Stimulation with the EP1/EP3 receptor agonist sulprostone resulted in a significant increase of chondrocyte [³H]-thymidine incorporation, whereas the EP2/EP3 receptor agonist misoprostole had an intermediate effect and the EP2 agonist butaprost exerted no effect (Figure 6a). These obser-
vations were further supported by the use of EP receptor sub-
type-specific ligands. The EP1 agonist ONO-D1-004, and to
a lesser extent the EP2 agonist ONO-AE1-259-01 and the
EP3 agonist ONO-AE-248, significantly increased [3H]-thymi-
dine incorporation whereas the EP4 selective agonist ONO-
AE1-329 exerted no effect. The proliferative activity of the EP1
agonist ONO-D1-004 was similar to maximal stimulation
achieved by PGE2. In support of this observation, the addition
of the selective EP1 antagonist ONO-8713 completely
blocked PGE2-induced proliferation (Figure 6b).

Expression of EP1 and EP2 receptors
The expression of the different EP receptors was studied at
the mRNA level by PCR and at the protein level by immunohis-
tochemistry. The specificity of the antibodies used was
assessed by omitting the first antibody and by preabsorbing
with the corresponding peptide against which the antibody
was generated. Under both conditions specific staining was
absent (data not shown). Growth plate tissue as well as cul-
tured chondrocytes showed expression of EP1 and EP2
receptor mRNA detected by reverse transcription-PCR (Fig-
ure 7). Regarding protein expression of the EP1 and EP2
receptors, the antibody against the EP2 receptor labelled all
zones of the eiphyseal growth plate in a homogeneous man-
ner. EP1 expression showed a different expression pattern,
with strong expression in the proliferative and hypertrophic
zone and only moderate expression in the reserve zone, occa-
sionally with EP1 negative cells (Figure 8). In cultured
chondrocytes, staining for EP1 was intense in confluent poly-
gonal cells, which were organised in a cobblestone pattern and
surrounded by matrix, whereas fibroblastic shaped cells were
only occasionally positive. The EP2 receptor protein was
expressed in distinct chondrocytes only. High expression was
detected in dividing cells and polygonal chondrocytes embed-
ded in matrix, whereas fibroblastic, and less differentiated
chondrocytes showed only marginal staining in a small number
of cells.

Expression of EP3 and EP4 receptors
Growth plate tissue as well as cultured chondrocytes showed
expression of EP3 and EP4 receptor mRNA, although the
amplification product for EP3 appeared to be less intense in
the chondrocytes (Figure 9). In growth plates, EP3 and EP4
receptors were expressed in all layers (Figure 10). In cultured
chondrocytes, a weak staining for both types of receptor was
visible (Figure 9). Only distinct cells, which represent less than
10%, exhibited a strong reaction against the antibodies used.

Discussion
The present study clearly demonstrates that growth plate
chondrocytes are capable of secreting PGE2. The effects of
PGE2 are mediated by G-protein-coupled receptors with dif-
ferent pathways of signal transduction. The present data show
for the first time expression of COX-1 and COX-2, as well as EP1, EP2, EP3 and EP4, in the intact growth plate \textit{in situ} in comparison with the expression in cultured growth plate chondrocytes. COX enzymes are expressed \textit{in situ} in a characteristic spatial distribution: whereas COX-1 is homogeneously expressed in all zones of the growth plate, COX-2 showed moderate expression in the reserve zone and strong expression in the other zones. Regarding EP receptor expression, EP1 expression \textit{in situ} was mainly restricted to the proliferative and hypertrophic zone. Contrasting with this, EP2, EP3 and EP4 receptors \textit{in situ} were homogeneously expressed by all chondrocytes, but \textit{in vitro} by a subpopulation of cells only.

Collagen expression was analysed as a parameter of the phenotypic integrity of the chondrocytes and Col II and Col X are expressed in specific maturation states. In our system, the differentiation state of the majority of cells corresponded to cells in the proliferative layer, as shown previously [33]. This is confirmed not only by the proliferative activity but also by the production of Col II, and the lack of Col X, which is a specific marker of late hypertrophic chondrocytes [34]. Col I is not believed to be characteristically expressed in the growth plate and costochondral cartilage, but rather in the superficial layer of mandibular and articular cartilage [35]. Col I was also detectable in our cultured cells, which indicates the presence of ‘de-differentiated’ chondrocytes [28] in the absence of Col X expression.

PGE$_2$ is produced by COX, of which two isoforms – COX-1 and COX-2 – exist. However, its protein expression has not been demonstrated previously in the growth plate, despite the fact that secreted prostanoids, which were generated by COX-1 and/or COX-2, were shown to modulate chondrocyte proliferation and function in \textit{in vitro} systems. These results can only be extrapolated to the \textit{in situ} situation if COX is expressed in the intact growth plate. Using polyclonal antibodies to COX-1 and COX-2, we were able to demonstrate COX-1 and COX-2 immunoreactivity in growth plate chondrocytes. Paralleling the \textit{in situ} situation, both COX-1 and COX-2 mRNA as well as COX-1 and COX-2 protein were expressed in cultured chondrocytes. Concluding from the observed inhibitory effect of the COX-2 inhibitor SC-236, but not of the COX-1 inhibitor SC-560, on chondrocyte proliferation, we suggest that, at least for the cultured chondrocytes, COX-2 is the responsible enzyme driving PGE$_2$ formation.

In our primary culture system, PGE$_2$ stimulated DNA synthesis in a bell-shaped manner, the strongest effect being observed at concentrations that are higher than those physiologically found in the circulation [36]. These results are in accordance with studies by O’Keefe and colleagues [7] and Schwartz and colleagues [6], describing a growth-stimulatory effect of PGE$_2$ at similar concentrations. We speculate, therefore, that secreted PGE$_2$ could function as an autocrine/paracrine mediator of chondrocyte proliferation. From \textit{in vitro} studies it is well known that PGE$_2$ may have different concentration-dependent effects on cell proliferation and matrix synthesis. This implies that local PGE$_2$ concentrations in the various zones of the growth plate may differ. In fact, bovine chondrocytes isolated from the ‘superficial zone’ of the growth plate, that is, mainly reserve zone cells, were shown to produce less PGE$_2$ than...
Table 2

| Incubation time | PGE₂ (µg/ml) | Proliferation status |
|-----------------|--------------|----------------------|
| 0               | 120 ± 20     |                      |
| 2 days          | 530 ± 270*   | Rapidly proliferating|
| 6 days          | 150 ± 30     | Slowly proliferating  |

Chondrocytes were seeded in culture plates and fresh medium was added. At different time points supernatant was collected and analyzed for prostaglandin E₂ (PGE₂) content (n = 6; *p < 0.01 versus day 0).

Corresponding to the proposed proliferative action of PGE₂ via the EP1 receptor, this receptor could be demonstrated at the mRNA and protein levels not only in vitro but also in situ. In the intact growth plate we observed a strong EP1 receptor immunoreactivity in proliferative and hypertrophic chondrocytes, but not in reserve zone cells. This is in line with the proliferative effect of PGE₂ mediated via the EP1 receptor. In vitro, EP1 was expressed in all cells, although the intensity varied. Because in our culture system proliferative cells represented the majority of chondrocytes, the ubiquitous expression of EP1 receptor in situ was in contrast to the in vitro situation. This discrepancy indicates that extrapolation of the in vitro data to the in situ situation should be done with caution.

In addition, the EP2 receptor also showed a different expression pattern in situ and in vitro. The EP2 receptor was not uniformly detectable in vitro, although in situ all cells were positive. The highest expression was observed in dividing cells. It can be concluded from our data that EP2 receptor signalling also contributes to cell growth. The inhomogenous expression of EP2 in cultured chondrocytes may explain the lower proliferative effect achieved by the specific EP2 agonist. EP2 receptor expression has also been described in cultured articular chondrocytes [43] and fourth passage reserve zone cells [44]. In the latter, PGE₂ stimulated intracellular cAMP, which resulted in increased matrix synthesis. In a chondrocyte cell line, established from articular cartilage of p53⁻/⁻ mice, the EP2 receptor was identified as the major PGE₂ receptor [45]. In this cell line, EP2 agonists evoked cAMP generation and promoted cell growth. In articular chondrocytes, PGE₂ probably mediates its proliferative effect primarily via the EP2 receptor whereas in growth plate chondrocytes the EP1 receptor is dominant for PGE₂-dependent growth. EP2 and EP4 receptors may also be involved in chondrogenesis [39]. In limb bud mesenchymal cells, all four types of EP receptor are expressed and EP2 and EP4 receptor activation of cAMP metabolism was suggested to drive mesenchymal stem cells to chondrogenesis. We observed a weak expression of the EP4 receptor in our cultured chondrocytes. Most likely, EP receptors, and especially the EP4 type, are expressed depending on the cell differentiation state in culture. By contrast, in the growth plate tissue of the rat we observed EP4 expression in all layers. In a recent study, Miyamoto and colleagues [20] showed that the EP2 receptor promotes differentiation and synthesis of Col II and proteoglycans in cultured bovine growth plate cells. This effect was dependent on co-stimulation of the EP4 receptor; however, in rat, the EP4 receptor was not detected, at least in fourth passage chondrocytes [46]. In view of these results, a role for the EP2 receptor in chondrocyte differentiation can be hypothesised. The differentiation-dependent expression of EP receptors might explain the contradictory results obtained in studies investigating the effects of PGE₂. This indicates the crucial role played by species and culture conditions used in the various in vitro systems. According to our in vivo data, all...
types of EP receptors appeared to be expressed. Taking into account that the different EP receptors are coupled to different intracellular signalling pathways, we expect that other mechanisms, such as receptor activation, modulation of ligand affinity or selective access of PGE₂ to the necessary receptor type, are involved in ensuring a coordinated action of PGE₂ in growth plate physiology.

Conclusion
Cultured growth plate chondrocytes synthesized PGE₂. Exogenous PGE₂ stimulation had a proliferating-inducing effect in a dose-dependent manner on cultured growth plate chondrocytes via the EP1 receptor, which could be mimicked by EP agonists such as sulprostone and ONO-D1-004. The proliferating effects could be blocked by the EP1 antagonist ONO-8713.

Further analyses of the physiological and pathophysiological roles of EP1 and EP2, especially in chronic inflammatory disorders, are needed. From a therapeutic point of view, the long-term effects of COX inhibitors and EP antagonists with respect to the integrity of the growth plate in the paediatric term effects of COX inhibitors and EP antagonists with orders, are needed. From a therapeutic point of view, the long-term effects of COX inhibitors and EP antagonists with respect to the integrity of the growth plate in the paediatric population is of special interest. Growth plate chondrocytes express COX-1, COX-2 and EP1, EP2, EP3, and EP4 in vitro and in situ with markedly different expression patterns. Therefore, the extrapolation from in vitro data to the in situ situation and the interpretation regarding physiological processes must be done with caution.

With respect to the possibilities for cartilage regeneration in the context of tissue engineering of bone and cartilage, the present data open interesting new aspects for optimising the seeding of scaffolds via stimulation of cell proliferation by PGE₂ or EP1 ligands; at present, this is under investigation. The analysis of arachidonic metabolites in the growth plate in vitro and in situ presents a wide scope for further investigations with pathophysiological, therapeutic and regenerative end points.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CB and PN made substantial contributions to the conception and design of experiments, data acquisition, analysis and interpretation; they were also involved in manuscript drafting and revising and contributed equally to this work. RMN performed statistical analysis, made substantial contributions to analysis and interpretation of data and was involved in drafting the manuscript. CJK was involved in data interpretation, drafting the manuscript and revised it critically for the physiological and pathophysiological impact of the data. GK made substantial contributions to the conception and design of the experiments as well as to interpretation of data and was involved in drafting the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We kindly thank Ulrike Hügel for her excellent technical assistance and Bernhard Watzer and Horst Schweer for their valuable help in PGE₂ determination.

References
1. Klein DC, Raiaz LG: Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology 1970, 86:1436-1440.
2. Flanagan AM, Chambers TJ: Stimulation of bone nodule formation in vitro by prostaglandins E1 and E2. Endocrinology 1992, 130:443-448.
3. Weinreb M, Rutledge SJ, Rodan GA: Systemic administration of an anabolic dose of prostaglandin E(2) induces early response genes in rat bones. Bone 1997, 20:347-353.
4. Igarashi K, Hirafui M, Adachi H, Shinoda H, Mitani H: Role of endogenous PGE2 in osteoblastic functions of a clonal osteoblast-like cell, MC3T3-E1. Prostaglandins Leukot Essent Fatty Acids 1994, 50:169-172.
5. Lowe GN, Fu YH, McDougall S, Polendo R, Williams A, Benya PD, Hahn TJ: Effects of prostaglandins on deoxyribonucleic acid and aggrecan synthesis in the RCJ 3.1C5.18 chondrocyte cell line: role of second messengers. Endocrinology 1996, 137:2208-2216.
6. Schwartz Z, Gallely RM, Sylvia VL, Dean DD, Boyan BD: The effect of prostaglandin E2 on costochondral chondrocyte differentiation is mediated by cyscal pain 3,5-monophosphate and protein kinase C. Endocrinology 1998, 139:1825-1834.
7. O’Keefe RF, Crabil ID, Puzas JE, Rosier RN: Influence of prostaglandins on DNA and matrix synthesis in growth plate chondrocytes. J Bone Miner Res 1992, 7:397-404.
8. Ueda K, Saito A, Nakano H, Aoshima M, Yokota M, Muraoka R, Iwata T: Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease. J Pediatr 1980, 97:334-336.
9. Suponitzky I, Weinreb M: Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. J Endocrinol 1998, 156:51-57.
10. Marks SC Jr, Miller S: Local infusion of prostaglandin E1 stimulates mandibular bone formation in vivo. J Oral Pathol 1988, 17:500-505.
11. Yang RS, Liu TK, Lin-Shiau SY: Increased bone growth by local prostaglandin E2 in rats. Calcif Tissue Int 1993, 52:57-61.
12. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120.
13. Sylvia VL, Del Toro F, Dean DD, Hardin RR, Schwartz Z, Boyan BD: Effects of 1alpha,25-(OH)(2)D(3) on bone mass and calcification. J Bone Miner Res 2002, 17:963-976.
14. Sakai T, Kambe F, Mitsuyama H, Ishiguro N, Kurokouchi K, Takigawa M, Iwata H, Sato H, Tamura T, Takakura R: PGE₂ induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-kappaB: abrogation of the tumor necrosis factor alpha effect by proteasome inhibitors. J Bone Miner Res 2001, 16:1272-1280.
15. Abelevic JP, Gaspard R, Healy ZR, Gaarde WA, Quackenbush J, Konstantopoulos K: Shear-induced cyclooxygenase-2 via a JNK2/c-Jun-dependent pathway regulates prostaglandin receptor expression in chondrocytic cells. J Biol Chem 2003, 278:28388-28394.
16. Siegle I, Klein T, Backman JT, Saal JA, Nüssing RM, Fritz P: Expression of cyclooxygenase 1 and cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 1998, 41:122-129.
17. Narumya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999, 79:1193-1226.
19. Yoshida K, Oida H, Kobayashi T, Maruyama T, Tanaka M, Katayama T, Yamaguchi K, Segi T, Tsuboyama T, Matsushita M, et al.: "Stimulation of bone formation and prevention of bone loss by prostaglandin E4 receptor activation." Proc Natl Acad Sci USA 2002, 99:4580-4585.

20. Miyamoto M, Ito H, Mukai S, Kobayashi T, Yamamoto H, Kobayashi M, Maruyama T, Aoyama H, Nakamura T: "Simultaneous stimulation of EP2 and EP4 is essential to the effect of prostaglandin E2 in chondrocyte differentiation." Osteoarthritis Cartilage 2003, 11:644-652.

21. Klaus G, von Eichel B, May T, Hügel U, Mayer H, Ritz E, Mehlis O: "Synergistic effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on proliferation and vitamin D receptor expression of rat growth cartilage cells." Endocrinology 1994, 135:1307-1315.

22. Erdmann S, Müller W, Bahrami S, Vornehm SI, Mayer H, Bruckner T, Serck-Hanssen H: "Differential effects of parathyroid hormone fragments on collagen gene expression in primary cultures of human growth plate chondrocytes." J Cell Biol 1996, 135:1179-1191.

23. Körnoff G, Gröne HJ, Klein T, Seyberth HW, Näser RM: "Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implications for renal function." Am J Physiol 1997, 272:F460-468.

24. Morath R, Klein T, Seyberth HW, Näser RM: "Immunolocalization of the four prostaglandin E2 receptor proteins, EP1, EP2, EP3, and EP4 in human kidney." J Am Soc Nephrol 1999, 10:1851-1860.

25. Kawamori T, Uchiya N, Kitamura T, Ohuchida S, Yamamoto H, Maruyama T, Sugimura T, Wakabayashi K: "Evaluation of a selective prostaglandin E receptor EP1 antagonist for potential properties in colon carcinogenesis." Anticancer Res 2001, 21:3856-3862.

26. Kiriyma M, Ushikubi F, Kobayashi T, Hirata M, Sugimura Y, Narumiya S, Obschaa A, Naraa M, Suda T: "Signaling specificity of the eight types and subtypes of the mouse prostaglandin receptor expressed in Chinese hamster ovary cells." Br J Pharmacol 1997, 121:27-34.

27. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T: "Cloning and expression of cDNA for the mouse prostaglandin receptor EP1 in bovine chondrocytes." J Bone Miner Res 2001, 16:221-227.

28. Benya PD, Shaffer JD: "Dedifferentiated chondrocytes reexpress the differentiated collagen phenotype when cultured in agarose gels." Cell 1982, 30:215-224.

29. Bohme K, Conscon-Egi M, Tschan T, Winterhalter KH, Bruckner P: "Induction of proliferation or hypertrophy of chondrocytes in serum-free culture: the role of insulin-like growth factor-I, insulin, or thyroxine." J Cell Biol 1996, 135:1307-1315.

30. Bittner F, Brochhausen C, Kohler H, Lehr HA, Otto M, Skarke C, Walgenbach S, Kirkpatrick CJ: "Differential expression of cell adhesion molecules in inflamed appendix: correlation with clinical stage." J Pathol 1998, 186:422-428.

31. Scherer H, Walser B, Seybert HW: "Determination of seven prostaglandins in 1 ml of urine by gas chromatography-negative ion chemical ionization triple stage quadrupole mass spectrometry." J Chromatogr 1994, 652:221-227.

32. Balmain N, von Eichel B, Toury R, Belguasmi F, Haucheconne M, Klaus G, Mehlis O, Ritz E: "Calbindin-D28K and -D9K and alkaline phosphatase and monoclonal anti-alkaline phosphatase monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes)." J Histochem Cytochem 1984, 32:219-229.

33. Blosser F, Brochhausen C, Kohler H, Lehr H, Otto M, Skarke C, Waldenbach S, Kirkpatrick CJ: "Differential expression of cell adhesion molecules in inflamed appendix: correlation with clinical stage." J Pathol 1998, 186:422-428.

34. O'Keefe RJ, Pujas J, Loveys L, Hicks DG, Rosier RN: "Analysis of type II and type X collagen synthesis in cultured growth plate chondrocytes by rapid induction of transcription and translation in long-term primary cultures of rat epiphyseal chondrocytes." Bone 1995, 17:37-45.

35. Ofek J, Pujas J, Loveys L, Hicks DG, Rosier RN: "Analysis of type II and type X collagen synthesis in cultured growth plate chondrocytes by rapid induction of transcription and translation in long-term primary cultures of rat epiphyseal chondrocytes." Bone 1995, 17:37-45.

36. Schweer H, Kamm J, Kühl P, Seybert HW: "Determination of peripheral plasma prostaglandin concentration: an unreliable index of "in vivo" prostaglandin activity." Eur J Clin Pharmacol 1986, 31:303-305.

37. Chowdhury TT, Bader DL, Lee DA: "Dynamic compression counteracts IL-1 beta-induced release of nitric oxide and PGE2 by superficial zone chondrocytes cultured in agarose constructs." Bone 1999, 25:261-267.

38. Watabe A, Sugimoto Y, Honda I, Arie I, Namba T, Negishi M, Ito S, Narumiya S, Ichikawa A: "Cloning and expression of CD4 for a mouse EP1 subtype of prostaglandin E receptor." J Biol Chem 1993, 268:20175-20181.

39. Clark CA, Schwartz EM, Zhang X, Ziran NM, Drissi H, O'Keefe RJ, Zosuch MJ: "Differential regulation of EP receptor isoforms during chondrogenesis and chondrocyte maturation." Biochem Bioph Res Com 2005, 328:764-776.

40. Funk CD, Fürchi L, FitzGerald GA, Gyoroczky R, Rochette C, Bayne MA, Abramovitz M, Adam M, Metters KM: "Cloning and expression of a CD4 for the human prostaglandin E receptor EP1 subtype." J Biol Chem 1993, 268:26767-26772.

41. Klaus G, König B, Hügel U, Ritz E, Mehlis O: "Intermittent and continuous exposure to 1,25(OH)2D3 have different effects on growth plate chondrocytes in vitro." Kidney Int 1993, 44:708-715.

42. Schwartz Z, Gilley RM, Sylvia VL, Dean DD, Boyan BD: "Prostaglandins mediate the effects of 1,25(OH)2D3 and 24,25-(OH)2D3 on growth plate chondrocytes in a metabolite-specific and cell maturation-dependent manner." Bone 1999, 24:475-484.

43. de Brum-Fernandes AJ, Morissett S, Bkaity G, Paty C: "Characterization of the PGE2 receptor subtype in bovine chondrocytes." Osteoarthritis Cartilage 2001, 11:488-496.

44. Del Toro F Jr, Sylvia VL, Schubkegel SR, Campos R, Dean DD, Boyan BD, Schwartz Z: "Characterization of prostaglandin E2 receptors and their role in 24,25-(OH)2D3-mediated effects on releasing zone chondrocytes." J Cell Physiol 2000, 182:218-224.

45. Aoyama T, Liang B, Okamoto T, Matusmaki T, Nishio K, Ishibe T, Yasuro K, Nagayama S, Nakayama T, Nakamura T, et al.: "PGE2 signal through EP2 promotes the growth of articular chondrocytes in vivo." J Bone Miner Res 2005, 20:377-389.

46. Sylvia VL, Del Toro F Jr, Hardin RR, Dean DD, Boyan BD, Schwartz Z: "Characterization of PGE2 receptors (EP) and their role as mediators of 1alpha,25-(OH)2D3(3) effects on growth zone chondrocytes." J Steroid Biochem Mol Biol 2001, 78:261-274.